Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.
Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD and Susan Owenby, RN, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.
Breast
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
| NSABP B-51/RTOG 1304 |
NCT01872975 |
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy |
Grant Clark, MD |
| S1418/BR006 |
NCT02954874 |
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy |
David Chism, MD |
|
NRG-BR004
|
NCT03199885
|
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
|
David Chism, MD
|
COVID-19
Gastrointestinal
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
| A021502 |
NCT02912559 |
Randomized Trial of Standard Chemotherapy alone or combined with Atezolizumab as adjuvant therapy for patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair(ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) |
David Chism, MD |
| NRG-GI005 |
NCT04068103 |
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) |
David Chism, MD |
Genitourinary
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
| NRG-GU005 |
NCT03367702 |
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer |
Grant Clark, MD |
Gynecologic
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
| NRG-GY009 |
NCT02839707 |
A Randomized, Phase 11/111 Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer |
Brook Saunders, MD |
Leukemia/Lymphoma
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
| AZA-MDS-006 (CONNECT) |
NCT01688011 |
The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry |
David Chism, MD |
Lung: Small Cell
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
| NRG-CC003 |
NCT02635009 |
A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer |
Grant Clark, MD |
| NRG-LU005 |
NCT03811002 |
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab |
Grant Clark, MD |
Lung: Non-Small Cell
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
| D910LC00001 (MeRmaiD1) |
NCT04385368 |
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1) |
David Chism, MD |
| MK7339-006 |
NCT03976323 |
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (MK7339-006 / KEYLYNK 006) |
David Chism, MD |
| MK7339-008 |
NCT03976362 |
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) |
David Chism, MD |
| MK7902-008 |
NCT03976375 |
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic Non- Small Cell Lung Cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008) |
David Chism, MD |
| D4194C00008 (OnTRAX) |
NCT04381494 |
Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab |
David Chism, MD |
Melanoma
| Protocol Number |
NCT Number |
Title |
Principal Investigator |
DREAMseq
EA6134 |
NCT02224781 |
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial |
David Chism, MD |
| EA6141 |
NCT02339571 |
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
David Chism, MD |